Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS

Journal of the American Medical Association

Volumn 279, Issue 20, 1998, Pages 1615-1622

  Downs, John R ^a   Clearfield, Michael ^b   Weis, Stephen ^b   Whitney, Edwin ^c   Shapiro, Deborah R ^d   Beere, Polly A ^d   Langendorfer, Alexandra ^d   Stein, Evan A ^e   Kruyer, William ^f   Gotto Jr , Antonio M ^g  

^a WILFORD HALL MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH TEXAS   (United States)

^c Heart and Vascular Institute of Texas   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e Metabolic and Atherosclerosis Research Center   (United States)

^f Air Force Materiel Command   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN;

ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; UNSTABLE ANGINA PECTORIS;

AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DIET, FAT-RESTRICTED; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOVASTATIN; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REFERENCE VALUES; RISK FACTORS; TRIGLYCERIDES;

EID: 0032572086     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.20.1615     Document Type: Article

References (20)

1. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol. 1995;76:69C-77C.
2. Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med. 1995;332: 512-521.
3. Chen ZM, Peto R, Collins R, MacMahon S, Lu JR, Li WX. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ. 1991;303:276-282.
4. Stamler J, Wentworth D, Neaton JD, for the MRFIT Research Group. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded?: findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Study (MRFIT). JAMA. 1986;256:2823-2828.
5. Castelli WP. Cardiovascular disease in women. Am J Obstet Gynecol. 1988;158:1553-1560.
6. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 participants with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
7. Sacks FM, Pfeffer MA, Moye LA, et al.. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
8. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
9. Whitney EJ, Shear CL, Mantell G, et al. The case for unstable angina pectoris as a primary endpoint in primary prevention studies. Am J Cardiol. 1992; 70:738-743.
10. Downs JR, Beere PA, Whitney E, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): design and rationale. Am J Cardiol. 1997;80:287-293.
11. Sempos CT, Cleeman JI, Carroll MD, et al. Prevalence of high blood cholesterol among US adults. JAMA. 1993;269:3009-3014.
12. Myers GL, Cooper GR, Winn CL, Smith SJ. The Centers for Disease Control-National Heart, Lung, and Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements. Clin Lab Med. 1989;9:105-135.
13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem. 1972;18: 499-502.
14. National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988-94, US NHANES III Examination Data File [CD-ROM]. Hyattsville, Md: Centers for Disease Control and Prevention; 1996. DHHS public use data file 76200.
15. Clearfield M, Whitney E, Weis S, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): baseline characteristics. Submitted.
16. National Cholesterol Education Program Expert Panel. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
17. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in incidence of coronary heart disease. JAMA. 1984;251:351-364.
18. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317:1237-1245.
19. LaRosa JC, Hunninghake D, Bush D, et al. The cholesterol facts. Circulation. 1990;81:1721-1733.
20. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results, I: efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1991;151:43-49.